Martin Lasak

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Factor VIII (FVIII) replacement by continuous infusion has been advocated as a cost-effective method for maintaining stable plasma levels of FVIII in the hemophilia A patients during surgery or life-threatening hemorrhage. Continuous delivery of monoclonal or recombinant FVIII concentrates to our pediatric patients using a traditional delivery system(More)
  • 1